Strategies Targeting Protein Tyrosine Phosphatase SHP2 for Cancer Therapy
Yihui Song, Shu Wang, Min Zhao et al. · Journal of Medicinal Chemistry · 2022
is a promising therapeutic target for cancer therapy, while the multifaceted roles of SHP2 complicate the drug discovery targeting SHP2. Given the biological significance of SHP2, strategies targeting SHP2 have been developed in recent years. To date, eight SHP2 inhibitors have advanced into clinical trials as mono- or combined therapy for treating solid tumors or adaptive resistant cancers. In this Perspective, we briefly summarize the strategies targeting SHP2 including inhibitors, activators, and proteolysis-targeting chimera (PROTAC) degraders. Besides, targeting the protein-protein interactions between SHP2 and other adaptor proteins is also discussed. Finally, we also highlight the target- and pathway-dependent combination strategies of SHP2 for cancer therapy. This Perspective may provide a timely and updated overview on the strategies targeting SHP2 for cancer therapy.
Cited by 89 works. doi:10.1021/acs.jmedchem.1c02008
Authors
References
- Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome
- Crystal Structure of the Tyrosine Phosphatase SHP-2
- Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia
- Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases
- Protein-tyrosine phosphatases and cancer
- Targeted protein degradation: expanding the toolbox
- PTPN11 is the first identified proto-oncogene that encodes a tyrosine phosphatase
- Molecular Mechanism for a Role of SHP2 in Epidermal Growth Factor Receptor Signaling
- RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers
- The role of Shp2 (PTPN11) in cancer